retatrutide triple agonist glp-1 gip glucagon #retatrutide is a novel peptide at the receptor, receptor, and receptor. 22-24% weight loss at 48 weeks with a similar tolerability profile to #tirzepatide. @LillyPad #medtwitter #endotwitter https://t.co/duYwW0EcmF Retatrutide is a triple-agonist drug

For example, in the SELECT cardiovascular outcome trial studying people with obesity, the extent of weight loss did not correlate with the effects of the drug to reduce heart attack, stroke, and cardiovascular death . Also, another long-acting GLP-1 therapy, albiglutide, [was] withdrawn from the market owing to modest efficacy for reduction of glucose and body weight in people with T2D

Hexarelin is a synthetic growth hormone-releasing peptide with protective effects in the cardiovascular system and nervous system and stimulating effects on growth [1, 2]

The body improves when its in a recovered state

And remember, dont stop taking your GLP-1 medication without consulting your doctor

Impact: Irregular use slows the buildup of glutathione levels in the body

Detailed Protocol